転移性前立腺がん(Metastatic Prostate Cancer)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Metastatic Prostate Cancer Overview 8
Therapeutics Development 9
Pipeline Products for Metastatic Prostate Cancer – Overview 9
Pipeline Products for Metastatic Prostate Cancer – Comparative Analysis 10
Metastatic Prostate Cancer – Therapeutics under Development by Companies 11
Metastatic Prostate Cancer – Therapeutics under Investigation by Universities/Institutes 13
Metastatic Prostate Cancer – Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Metastatic Prostate Cancer – Products under Development by Companies 17
Metastatic Prostate Cancer – Products under Investigation by Universities/Institutes 18
Metastatic Prostate Cancer – Companies Involved in Therapeutics Development 19
Actinium Pharmaceuticals, Inc. 19
Camurus AB 20
Colby Pharmaceutical Company 21
Eli Lilly and Company 22
Fountain Biopharma Inc. 23
Johnson & Johnson 24
MedImmune, LLC 25
MEI Pharma, Inc. 26
OncoMax 27
OXiGENE, Inc. 28
Progenics Pharmaceuticals, Inc. 29
ValiRx Plc 30
Metastatic Prostate Cancer – Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
abiraterone acetate – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Actimab-P – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
CADD-522 – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Cell Therapy to Target PSMA for Metastatic Prostate Cancer – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
CPC-410 – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
FB-704A – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
KGP-94 – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
leuprolide acetate – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
LU-901 – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
LY-2495655 – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
MEDI-6469 – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
MIP-1095 – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
MVI-118 – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
OMRCA-01 – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
pracinostat – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Recombinant Protein for Oncology – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
VAC-1 – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Vaccine For Oncolytic Newcastle Disease Virus – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
VAL-201 – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Metastatic Prostate Cancer – Recent Pipeline Updates 65
Metastatic Prostate Cancer – Dormant Projects 75
Metastatic Prostate Cancer – Discontinued Products 76
Metastatic Prostate Cancer – Product Development Milestones 77
Featured News & Press Releases 77
Mar 27, 2014: OXiGENE Announces Presentation of Preclinical Abstracts at 2014 AACR Conference 77
Feb 06, 2014: ZYTIGA Now Reimbursed in Québec for Use Prior to Chemotherapy in Men with Metastatic Prostate Cancer 77
Nov 21, 2013: ZYTIGA Now Available for Men with Metastatic Prostate Cancer in British Columbia Prior to Chemotherapy 78
May 29, 2013: Janssen’s Zytiga Receives New Indication Approval From Health Canada For Treatment Of Metastatic Prostate Cancer 78
Jun 02, 2012: Zytiga’s Phase III Results Show Significant Improvement In Radiographic Progression-Free Survival And Trend For Increased Overall Survival In Metastatic Prostate Cancer Patients 80
May 16, 2012: J&J’s ZYTIGA Now Available For Eligible Patients In Nova Scotia, Newfoundland And Labrador For Prostate Cancer 81
Mar 04, 2005: Geron Announces Publication Of Phase 1-2 Telomerase Vaccine Study Results In Patients With Metastatic Prostate Cancer 81
Appendix 83
Methodology 83
Coverage 83
Secondary Research 83
Primary Research 83
Expert Panel Validation 83
Contact Us 84
Disclaimer 84